Top Markets
#1 Ontology Gas Ontology Gas +46.81%
#2 Verus Coin Verus Coin +22.52%
#3 EXOD EXOD +22.08%
#4 Fake World Assets Fake World Assets +22.08%
#5 ETHGas ETHGas +21.14%
#6 Status Status +17.96%
#7 Geodnet Geodnet +17.50%
#8 The Black Bull The Black Bull +16.80%
#9 Derive Derive +11.99%
#10 Ontology Ontology +11.87%
Coin of the day
Ontology Gas Ontology Gas
Settings
Language
ENGLISH
Currency
USD
Theme
AlloVir, Inc. AlloVir, Inc.

AlloVir, Inc.

ALVR
Rank in Stocks #25523
AlloVir, Inc. is a biotechnology company in the clinical stage, dedicated to... AlloVir, Inc. is a biotechnology company in the clinical stage, dedicated to researching and developing allogeneic, "off-the-shelf" multi-virus specific T-cell (VST) therapies. Its primary goal is to prevent and treat severe diseases caused by viral infections. The company's lead product, posoleucel, is an allogeneic, ready-to-use VST therapy designed to combat several significant viruses, including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Beyond this flagship candidate, AlloVir's pipeline features additional investigational treatments in various stages of development. These include ALVR106, which targets respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109, developed to address SARS-CoV-2 and COVID-19; ALVR107, for treating hepatitis B; and ALVR108. Established in 2013, the company was initially known as ViraCyte, Inc. before officially rebranding as AlloVir, Inc. in May 2019. Its headquarters are located in Waltham, Massachusetts.
Share Price
$9.81
Last synced: 2025-03-18
Market Cap
$48.68M
Change (1 day)
1.55%
Change (1 year)
0.00%
Country
US
Trade AlloVir, Inc. (ALVR)

Category

Healthcare
Revenue for AlloVir, Inc. (ALVR)
Revenue in Jun 2026 TTM: 0.00
According to AlloVir, Inc. latest financial reports the company's current revenue (TTM) is 0.00. In 2023 the company made a revenue of 0.00 equal to the revenue in the year 2022 that was 0.00. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for AlloVir, Inc. from 2018 to 2026
Revenue at the end of each year
Year Revenue Change
2026 (TTM) 0.00 0.00%
2024 0.00 0.00%
2023 0.00 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 -100.00%
2019 $165.00K -85.46%
2018 $1.14M 0.00%
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US